Aarkstore enterprise---Companion Biomarkers in Drug Development
by
neelPosted
Wed 27 Oct 2010 1:17am
Table of Contents :
1. Overview 13
1.1 Statement of Report 13
1.2 About This Report 13
1.3 Scope of the Report 13
1.4 Objectives 13
1.5 Methodology 15
1.6 Executive Summary 16
2. Introduction: Companion Diagnostics in Drug Development 19
2.1 Companion Diagnostics as Biomarkers 20
2.1.1 Potential Ben ...
Read on »
Companion Biomarkers in Drug Development --- Aarkstore Enterprise
by
aarks222Posted
Fri 19 Nov 2010 10:34am
The term “companion biomarker” means that a particular diagnostic test is specifically linked to a therapeutic drug either in drug development or in the clinic. Biomarkers of disease have long played an important role in diagnostic medicine as evidenced by the intense use of specific clinical laboratory tests in the diagnosis of disease. Biom ...
Read on »
Companion Diagnostics in Personalized Medicine and Cancer Therapy --- Aarkstore Enterprise
by
aarks222Posted
Fri 19 Nov 2010 11:17am
A near-term market opportunity for cancer companion diagnostic tests exists in drug selection for cancer therapy. Co-development of molecular diagnostics and targeted therapeutics has already been proven to be a successful strategy in the development of novel anti-cancer drugs. Adoption of biomarker development in clinical research provides g ...
Read on »
Personalized Medicine --- Aarkstore Enterprise
by
aarks222Posted
Wed 24 Nov 2010 4:27am
Personalized medicine and pharmacogenomics are inextricably linked. Pharmacogenomics is the use of genetic variations (such as SNPs, gene expression variability, or other molecular signatures) to understand and correlate with differential response to pharmaceutical agents (drugs). Pharmacogenomics can be deployed clinically to stratify patien ...
Read on »
Risk Factors for Enhanced CV Mortality in ESRD Patients
by
Matt S.Posted
Mon 26 Jan 2009 12:00am
Cardiovascular mortality in the general ESRD population is between 10- and 20-fold higher than that of the general population, and is an astounding 65-fold higher in ESRD individuals in the 45-54-year-old subgroup of the Framingham study. A recent review lists some of the risk factors which have been targeted as being contributers to this enh ...
Read on »
New data on prostate cancer vaccine BPX-101
by
Dr. Arnon KrongradPosted
Mon 19 Apr 2010 12:00am
Straight from a “late-breaking poster” at the annual meeting of the Association for the Advancement of Cancer Research going on in Washington, DC, comes data about BPX-101 another dendritic cell-based immunotherapeutic “vaccine” for the possible treatment of late-stage prostate cancer.
BPX-101 is in development by Bellic ...
Read on »
Biomarker Technology Platforms for Cancer Diagnoses and Therapies --- Aarkstore Enterprise
by
aarks222Posted
Thu 18 Nov 2010 9:49am
Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred ...
Read on »
Chest Pain: Admission versus Discharge
by
Mark LevinPosted
Tue 23 Mar 2010 1:46pm
Chest pain accounts for approximately 6 million annual visits to emergency departments (ED) in the United States (US), making chest pain the second most common complaint. ED evaluation focuses on distinguishing and admission of life-threatening causes of chest pain; others can be worked up on the outpatient basis.
The published guidelin ...
Read on »
Population Health Management Journal Summarized Again!
by
JaanSPosted
Sun 28 Nov 2010 6:33pm
It took a while and it needed some much needed breathing space, but the Disease Management Care Blog finally stopped looking guiltily at its unread October issue of the Population Health Management Journal and finally cracked the cover. It knows it's not the only one battling a very busy time of year and that there are holidays to contend with. ...
Read on »